Events - Pharvaris N.V.

Past Events

Mar 19 - Mar 21, 2026

Italian Network for Hereditary and Acquired Angioedema (ITACA) 5th ITACA National Congress

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 267.6 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study 450.9 KB

Mar 11, 2026 9:20 AM EDT

Leerink Global Healthcare Conference 2026

Click for Webcast

Mar 10, 2026 11:20 AM EDT

The Citizens Life Sciences Conference

Click here for webcast

Feb 27 - Mar 2, 2026

American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting

Supporting Materials

A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema 424.5 KB

Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks 416.5 KB

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 500.3 KB

Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study 593.7 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 446.9 KB

Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 523.1 KB

Feb 26, 2026 9:20 AM EST

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Click here for webcast

Feb 1 - Feb 5, 2026

Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study 221.7 KB

Dec 3, 2025 8:00 AM EST

Pharvaris Reports Topline RAPIDe-3 Data

Listen to webcast

Supporting Materials

RAPIDe-3 Topline Data Disclosure 1.4 MB

Dec 1 - Dec 2, 2025

2025 BSI Clinical Immunology Professional Network (BSI-CIPN) Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 226.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 329.8 KB

Nov 6 - Nov 10, 2025

American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1 660.2 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results 338.8 KB

Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 237.9 KB

Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 179.6 KB

Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results 229.3 KB

Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 553.5 KB

Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema 505.1 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension 523 KB

Oct 24 - Oct 26, 2025

Japanese Society of Allergology (JSA)

Supporting Materials

Deucrictibant vs. Standard of Care in HAE 633.8 KB

Oral Deucrictibant XR Tablet for Prophylaxis of HAE Attacks: CHAPTER-3 Phase 3 Trial Design 888.3 KB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page

Presentations

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema

Latest Corporate Presentation